Table 5.
Comparison of histopathology and outcome between benign insulinomas of group 1 (2000–2010) and group 2 (2011–2020)
| Variables | MIC group 1 (n = 7) |
MIC group 2 (n = 11) |
P value | Open group 1 (n = 29) |
Open group 2 (n = 10) |
P value |
|---|---|---|---|---|---|---|
| Tumor size in mmc | 15 (11–22) | 15 (11–23) | 0.492a | 14 (5–32) | 13 (7–30) | 0.935a |
| Resection status* | ||||||
| R0 | 3/4 (75%) | 10 (91.%) | 0.476b | 15/18 (83%) | 6/8 (75%) | 0.628b |
| R1 | 1/4 (25%) | 1 (9%) | 3/18 (17%) | 2/8 (25%) | ||
| Ki67 index* | ||||||
| G1 | 7 (100%) | 9 (82%) | 0.497b | 17/23 (74%) | 8 (80%) | 1.000b |
| G2 | 0 | 2 (18%) | 6/23 (26%) | 2 (20%) | ||
| Positive IHC for insulin* | 7 (100%) | 11 (100%) | 27/27 (100%) | 10 (100%) | ||
| Number of resected lymph nodesc | 0 (0–1) | 0 (0–5) | 0.804a | 1 (0–20) | 3 (0–13) | 0.173a |
| Median follow-upc | 140 (48–192) | 52 (13–89) | 190 (3–249) | 50.5 (1–110) | ||
| Disease status at evaluation point* | ||||||
| NED | 6 (86%) | 11 (100%) | 0.389b | 21/24 (87%) | 10 (100%) | 0.539b |
| DURC | 1 (14%) | 0 | 3/24 (13%) | 0 |
aMann-Whitney U test
bFisher’s exact test
cMedian with range (months)
IHC immunohistochemistry, NED no evidence of disease, DURC dead of unrelated causes
*Missing data